Glucotrack, Inc.
GCTK Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$1.61
KIRA · Stoqly’s AI analyst, in plain words
- Glucotrack, Inc. lost $19.4M in fiscal 2025.
- Free cash flow was −$15.3M in fiscal 2025, — of revenue.
Market cap
$8.1M
P/E
—
Revenue
—
Net income
−$19.4M
Free cash flow
−$15.3M
Operating margin
—
Glucotrack, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$19.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Glucotrack, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Glucotrack, Inc.
- CIK
- 0001506983
Glucotrack, Inc. · GCTK
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$4.1M | −$4.4M | −$7.1M | −$22.6M | −$19.4M |
| Diluted EPS | $0.26 | $0.29 | $34.18 | $4,106.00 | $31.22 |
| Cash | |||||
| Cash from operations | −$3.8M | −$3.7M | −$6.6M | −$12.5M | −$15.2M |
| Capital expenditure | $0.0M | $0.0M | — | $0.1M | $0.1M |
| Free cash flow | −$3.8M | −$3.7M | — | −$12.6M | −$15.3M |
| Share count change | 7,781.9% | −99.9% | −98.7% | −97.4% | 11,192.7% |
| Debt and strength | |||||
| Cash and short-term investments | $6.1M | $2.3M | $4.5M | $5.6M | $7.4M |
| Shareholders' equity | $5.2M | $1.2M | $3.2M | −$13.0M | $2.8M |
| Current ratio | 6.9x | 2.3x | 3.2x | 4.5x | 1.6x |
| Interest coverage | — | — | — | −330.6x | — |
| Returns and quality | |||||
| Return on equity | −57.5% | −138.9% | −320.6% | — | — |
| Return on tangible equity | −78.9% | 360.6% | −248.7% | — | −685.6% |
| Altman Z'' | −44.7 | −143.7 | −76.3 | −85.0 | −73.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Glucotrack, Inc. · GCTK
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.61 a share, the company is worth $8.1M.
Source: SEC EDGAR XBRL filings (CIK 0001506983). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.